ERCC1 as a biomarker for bladder cancer patients likely to benefit from adjuvant chemotherapy

被引：0
|
作者：
Jong-Mu Sun
Ji-Youn Sung
Se Hoon Park
Ghee Young Kwon
Byong Chang Jeong
Seong Il Seo
Seong Soo Jeon
Hyun Moo Lee
Jisuk Jo
Han Yong Choi
Ho Yeong Lim
机构：
[1] Sungkyunkwan University School of Medicine,Division of Hematology
[2] Sungkyunkwan University School of Medicine,Oncology, Department of Medicine, Samsung Medical Center
[3] Sungkyunkwan University School of Medicine,Department of Pathology, Samsung Medical Center
[4] Cancer Research Institute,Department of Urology, Samsung Medical Center
[5] Research Institute for Future Medicine,undefined
[6] Samsung Medical Center,undefined
来源：
BMC Cancer | / 12卷
关键词：
Bladder Cancer; Adjuvant Chemotherapy; Transitional Cell Carcinoma; ERCC1 Expression; Nucleotide Excision Repair Pathway;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] ERCC1 as a biomarker for bladder cancer patients likely to benefit from adjuvant chemotherapy
    Sun, Jong-Mu
    Sung, Ji-Youn
    Park, Se Hoon
    Kwon, Ghee Young
    Jeong, Byong Chang
    Seo, Seong Il
    Jeon, Seong Soo
    Lee, Hyun Moo
    Jo, Jisuk
    Choi, Han Yong
    Lim, Ho Yeong
    BMC CANCER, 2012, 12
  • [2] MDR1 and ERCC1 expression predict outcome in patients with locally advanced bladder cancer and adjuvant chemotherapy
    Hoffmann, Andreas C.
    Bertz, Simone
    Stohr, Robert
    Wild, Peter J.
    Lehmann, Jan
    Danenberg, Kathleen D.
    Denenberg, Peter V.
    Schuler, Martin
    Hartmann, Arndt
    CANCER RESEARCH, 2010, 70
  • [3] MDR1 and ERCC1 Expression Predict Outcome of Patients with Locally Advanced Bladder Cancer Receiving Adjuvant Chemotherapy
    Hoffmann, Andreas-Claudius
    Wild, Peter
    Leicht, Christina
    Bertz, Simone
    Danenberg, Kathleen D.
    Danenberg, Peter V.
    Stoehr, Robert
    Stoeckle, Michael
    Lehmann, Jan
    Schuler, Martin
    Hartmann, Arndt
    NEOPLASIA, 2010, 12 (08): : 628 - 636
  • [4] ERCC1 and the Prognosis for Patients With Colon Cancer Receiving Oxaliplatin-Based Adjuvant Chemotherapy
    Baek, Moo-Jun
    ANNALS OF COLOPROCTOLOGY, 2015, 31 (03) : 81 - 81
  • [5] ERCC1 polymorphisms in patients with advanced bladder cancer treated with platinum-based chemotherapy
    Bamias, A.
    Nikitas, N.
    Karadimou, A.
    Gika, D.
    Karavasilis, V.
    Briasoulis, E. C.
    Chrisofos, M.
    Murray, S.
    Pectasides, D. G.
    Dimopoulos, M. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [6] ERCC1 REMAINS A PREDICTIVE MARKER OF THE BENEFIT OF ADJUVANT CHEMOTHERAPY (CT) IN THE UPDATED INTERNATIONAL LUNG CANCER TRIAL (IALT)
    Soria, J. C.
    Olaussen, K. A.
    Vataire, A. L.
    Dunant, A.
    Pirker, R.
    Besse, B.
    Andre, F.
    Brambilla, E.
    Le Chevalier, T.
    Fouret, P.
    ANNALS OF ONCOLOGY, 2008, 19 : 92 - 92
  • [7] Prediction of response to chemotherapy by ERCC1 immunohistochemistry and ERCC1 polymorphism in ovarian cancer
    Steffensen, K. D.
    Waldstrom, M.
    Jeppesen, U.
    Brandslund, I.
    Jakobsen, A.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2008, 18 (04) : 702 - 710
  • [8] ERCC1 predicts outcome in patients with gastric cancer treated with adjuvant cisplatin-based chemotherapy
    Sara De Dosso
    Elena Zanellato
    Martina Nucifora
    Renzo Boldorini
    Angelica Sonzogni
    Roberto Biffi
    Nicola Fazio
    Eraldo Bucci
    Ottavio Beretta
    Stefano Crippa
    Piercarlo Saletti
    Milo Frattini
    Cancer Chemotherapy and Pharmacology, 2013, 72 : 159 - 165
  • [9] Prediction of response to chemotherapy by ERCC1 immunohistochemistry and ERCC1 polymorphism in ovarian cancer
    Waldstrom, M.
    Steffensen, K. D.
    Jeppesen, U.
    Brandslund, I.
    Jakobsen, A.
    APMIS, 2008, 116 (03) : 239 - 240
  • [10] Prediction of response to chemotherapy by ERCC1 immunohistochemistry and ERCC1 polymorphism in ovarian cancer
    Steffensen, K. D.
    Waldstrom, M.
    Jeppesen, U.
    Brandslund, I.
    Jakobsen, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
12345